Inx-315
WebDiscovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer. (PubMed, J Med Chem) Further, we detail the use of molecular dynamics simulations to provide insights into the basis for selectivity against CDK9. Based on overall potency, selectivity, and ADME profile, PF-06873600 (22) was identified as a candidate for the treatment ... Web9 feb. 2024 · Incyclix Bio (Incyclix) 正在开发 INX-315 作为一种口服的细胞周期蛋白依赖性激酶 2 (CDK2) 小分子抑制剂,用于治疗人类癌症。 这项首次人体研究旨在评估 INX-315 在复发...。临床试验注册。 ICH GCP。
Inx-315
Did you know?
Web6 apr. 2024 · 融资所得将用于支持 Incyclix Bio 的先导化合物 INX-315的临床开发,这是一种具有令人信服的临床前疗效和安全性数据的新型、强效和选择性 CDK2抑制剂。 Incyclix … Web4 apr. 2024 · Led by Patrick Roberts, Pharm.D., Ph.D., Chief Executive Officer and Co-Founder, Incyclix Bio is a cell cycle control company advancing precision treatments that target the aberrant proliferation...
WebWe're pleased to announce that the FDA has cleared an investigational new drug (#IND) application for our lead compound, INX-315, a novel, potent and… Liked by Yili Pritchett, Ph.D. Join now to ... WebThe L‑INX Automation Servers LINX‑153 and LINX‑154 are powerful, programmable automation stations, which can be programmed by L‑STUDIO. The L‑INX Automation …
Web28 feb. 2024 · INX-315-01 is a first-in-human, Phase 1/2 open-label, dose-escalation and dose-expansion study that will enroll patients with ER+/HER2- breast cancer that has progressed on a prior CDK4/6i... Web1 mrt. 2024 · INX-315-01 is a first-in-human, Phase 1/2 open-label, dose-escalation and dose-expansion study that will enroll patients with ER+/HER2- breast cancer that has progressed on a prior CDK4/6i regimen and patients with CCNE1-amplified solid tumors that have progressed on standard of care treatment.
Web28 feb. 2024 · The Phase 1/2 first-in-human study (INX-315-01) will assess the safety, pharmacokinetics, and preliminary antitumor activity of INX-315 in patients with …
WebStudy INX-315-01 is a first-in-human, Phase 1/2, open-label, dose escalation and dose-expansion study to evaluate the safety, PK, and preliminary antitumor activity of INX-315 … flip take two castle hillWebIncyclix Bio’s lead compound, INX-315, is a novel, potent and selective CDK2 with compelling pre-clinical efficacy and safety data. CDK2 is a known driver of abnormal … great falls bariatric clinicWeb4 apr. 2024 · INX-315 is a potent inhibitor of CDK2/cyclin E (0.6 nM biochemical IC50) with high selectivity over other CDK family members in both biochemical and intracellular … great falls balloon festival lewiston-auburnWeb9 feb. 2024 · Drug: INX-315 Detailed Description Study INX-315-01 is a first-in-human, Phase 1/2, open-label, dose escalation and dose-expansion study to evaluate the safety, … great falls barnes and nobleWeb9 mrt. 2024 · The M315KCA-E7B is a 32.0 inch diagonal a-Si TFT-LCD display panel product from Innolux Corporation (hereafter called Innolux ), with an integral WLED … great falls baseballWeb26 apr. 2024 · Incyclix Bio Announces FDA Clearance of Investigational New Drug Application for INX-315 in Patients with Advanced or Metastatic Cancer Liked by John E. Bisi So proud to work with our dedicated... fliptastics belle chasseWebApply to this Phase 1 & 2 clinical trial treating Cancer, Advanced, Metastatic Cancers, Hormone Receptor Positive Tumor, Ovarian Cancer, CCNE1 Amplification, Breast … fliptastics fitchburg ma